CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL

Condition:   B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma Intervention:   Biological: anti-CD19 UCAR-T injection Sponsors:   920th Hospital of Joint Logistics Support Force of People's Liberation Army of China;   Gracell Biotechnology Shanghai Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials